Xencor Inc

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune disease treatment. The company's marketed products include Ultomiris, approved for atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder, and Monjuvi for relapsed or refractory diffuse large B-cell lymphoma. These products generate the company's primary revenue streams, though Xencor remains primarily focused on pipeline development.

The pipeline includes multiple bispecific antibodies and T-cell engagers in Phase I and Phase Ib stages addressing oncology and autoimmune indications. Oncology candidates include XmAb819 for renal cell carcinoma, XmAb541 for ovarian cancer, Xaluritamig for prostate cancer, and plamotamab for rheumatoid arthritis. Additionally, Xencor has collaboration and licensing agreements with major pharmaceutical companies including Novartis and Johnson & Johnson covering multiple drug candidates, including ASP2138, JNJ-1493, and JNJ-9401.

Xencor was incorporated in Delaware in 1997 and maintains headquarters in Pasadena, California. The company operates primarily in the United States biopharmaceutical market. Specific employee count and geographic operating details are not publicly detailed, though the organization's scale reflects a typical clinical-stage biotech structure centered on research and development operations.